BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 15908667)

  • 1. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
    Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
    J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy.
    Argiris A; Li Y; Murphy BA; Langer CJ; Forastiere AA
    J Clin Oncol; 2004 Jan; 22(2):262-8. PubMed ID: 14722034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience.
    Papadimitrakopoulou VA; Dimery IW; Lee JJ; Perez C; Hong WK; Lippman SM
    Cancer J Sci Am; 1997; 3(2):92-9. PubMed ID: 9099459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck.
    Hitt R; Jimeno A; Millán JM; Castellano D; Cortés-Funes H
    Cancer; 2004 Aug; 101(4):768-75. PubMed ID: 15305408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
    Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Lawhorn K; Hong WK; Lippman SM
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-33-S19-37. PubMed ID: 9427263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A; Li Y; Forastiere A
    Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
    Kohno N; Kitahara S; Tamura E; Tanabe T; Nakanoboh M; Kawada M; Shirasaka T
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():592-9. PubMed ID: 10895216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.
    Benasso M; Ponzanelli A; Merlano M; Numico G; Ricci I; Vigo V; Grossi F; Amadori D; Cavallo G; Capaccetti B; Taveggia P; Boni L; Rosso R
    Acta Oncol; 2006; 45(2):168-74. PubMed ID: 16546862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan.
    Kiyota N; Tahara M; Kadowaki S; Fuse N; Doi T; Minami H; Ohtsu A
    Jpn J Clin Oncol; 2009 Apr; 39(4):225-30. PubMed ID: 19211574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Gu Y; Shu Y; Xu Q
    Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin and 5-FU infusion chemotherapy in advanced, recurrent cancer of the head and neck: an Eastern Cooperative Oncology Group Pilot Study.
    Rowland KM; Taylor SG; Spiers AS; DeConti RC; O'Donnell MR; Showel J; Stott PB; Milner LM; Marsh JC
    Cancer Treat Rep; 1986 Apr; 70(4):461-4. PubMed ID: 3698038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Galsky MD; Iasonos A; Mironov S; Scattergood J; Donat SM; Bochner BH; Herr HW; Russo P; Boyle MG; Bajorin DF
    Urology; 2007 Feb; 69(2):255-9. PubMed ID: 17320659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.